Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Preoperative Botensilimab with or without Balstilimab for Patients with Resectable, Locally Advanced pMMR or dMMR Colon Cancer: the UNICORN Trial by GONO
November 2, 2026
,
Ghelardi, F. et al.
Nature Medicine
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Botensilimab + Balstilimab in Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases: Extended Follow-Up and 3-Year Survival
ESMO
European Society of Clinical Oncology-Gastrointestinal Meeting (ESMO-GI)
July 2, 2026
,
Schlechter, B. et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer
Other Articles & Publications
Oncogene
June 16, 2026
,
Konecny, T. et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Artificial Intelligence (AI) foundation model as a predictor of efficacy of next generation checkpoint inhibition with botensilimab (BOT) + balstilimab (BAL) in solid tumors using pretreatment H&E images
ASCO
American Society of Clinical Oncology (ASCO)
May 31, 2026
,
Dalton R., et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
ASCO
American Society of Clinical Oncology (ASCO)
May 31, 2026
,
Atkins, M. et al.